Acromegaly defined as by chronic elevations of insulinlike growth factor-1 (IGF-1) and growth hormone (GH) that results in organomegaly. 1 Due to a higher risk of systemic complications, patients with acromegaly experience increased the rate of morbidity and mortality. 2, 3 Cardiovascular manifestations such as congestive heart failure, hypertension, and coronary artery disease are common complications in patients with acromegaly and cause 60% of the deaths in these patients. 4 The severity of cardiovascular manifestation related to the GH hypersecretion duration and mostly occurs in older patients with insufficient controlled acromegaly. 5 Recent studies showed the therapeutic efficacy of the early intervention, either surgical or medical, on systemic complications of acromegaly. [6] [7] [8] [9] However, acromegaly is a chronic syndrome lasting decades, and systemic complications may occur over the lifespan of patients. There is limited information regarding the effect of surgical resection of pituitary adenoma on cardiovascular comorbidities such as cardiomegaly in patients with acromegaly.
journals.sbmu.ac.ir/Neuroscience http IGF-I, and insuppressible GH serum levels during an oral glucose tolerance test. Chest X-ray and electrocardiogram and was obtained from all patients before and six months after surgery. The presence of pituitary adenoma confirmed by magnetic resonance imaging. In this study, cardiomegaly evaluated as a retrospective study of chest X-ray (PA) and cardiothoracic ratio (CTR) measurement of cardiac and mediastinal size ratios.
The exclusion criteria consisted of previously known cases of cardiomyopathy, diabetes mellitus, secondary hypertension, and usage of any preoperative medical treatment for acromegaly before the study.
Trans-sphenoidal surgery performed in all cases, and hormonal evaluation has done before and 6 months after surgical intervention.
Plasma GH level was measured by immunoradiometric assay with a detection limit of 0·2 mU/L, and plasma level of IGF-I by an RIA, respectively. IGF-I plasma levels of ≤ 463 µg/L (20-30 years), ≤ 370 µg/L (31-40 years), ≤ 306 µg/L (41-50 years) and ≤ 247 µg/L (> 50 years) considered as normal.
Patients with GH levels under 2 mU/L after a glucose load (75 g) and normal age-corrected IGF-I-values after six months considered as well-controlled cases.
In cases with a GH level > 5 μg/L, treatment continued by somatostatin octreotide after surgery. The patients were followed up in third and sixth months after surgery for evaluating symptoms relief and any case of tumor recurrence.
Results
During the study, 160 patients met the inclusion criteria. Their mean age was 39.1, and the standard deviation was 13.0. The patient's age ranged from 14 to 72 years old. The mean preoperative GH was 33.7 ml/ng, which reached 5.7 mL/ng after resection ( Figure 1 ).
The mean pre-operative hormone IGF-1 was 794.1 ml/ ng, which decreased 395.6 ml/ng postoperatively ( Figure  2 ). In this study, total tumor resection has done in 112 patients, subtotal resections in 42, and partial resections in 6 patients (Table 1) .
Of the 160 patients, 24 had preoperative cardiomegaly with a frequency of 15%, of which 30% postoperatively had a partial improvement in cardiac symptoms, and 21% had no change.
Discussion
Acromegalic cardiomyopathy is a common finding in all patients with GH secretive pituitary adenoma. The severity of cardiomyopathy is associated with the duration of disease and GH serum level before treatment. 1, 10 Cardiac complications of excess GH secretion such as heart failure and arrhythmias are the leading causes of death in patients with pituitary adenoma. Cardiac structure change in GH adenomas that occur even in the subclinical stages, including cardiac hypertrophy, chamber enlargement, ventricular diastolic dysfunction, and myocardial dysfunction. 10, 11 In this study, All of the patients had a high level of GH and IGF-1 and, 15 % of them had cardiomegaly that measured by chest X-ray.
Prompt diagnosis and therapeutic intervention are essential strategies inpatient with pituitary adenoma high level of GH. The first option of treatment in patients with acromegaly is endoscopic resection of pituitary adenoma. 12, 13 Removing as much tumor tissue as possible to reduce the serum level of GH to the normal range is 15, 16 Cardiac structural abnormalities and dysfunctional are correlate with excessive secretion of GH hormone. 17 Chronic elevation of serum GH and IGF-I due to pituitary adenoma could affect myocardium cell receptors, which increase myocardial sensitivity to intracellular Ca 2+ and results to increase myocardial contractility. On the other hand, increased protein synthesis and cell volume in myocardial cells result in myocardial hypertrophy. Also, excess GH secretion results in myocardial degeneration and necrosis, interstitial collagen accumulation, and fibrosis that lead to cardiac remodeling. 18 Currently, GH secretion control by surgical removal of the tumor is the treatment of choice in pituitary adenomas who complicated with acromegalic cardiomyopathy. In the current study, surgical resection of the pituitary adenoma and controlling GH secretion and serum levels of IGF-1, lead to recovered cardiac structure in some patients.
Our results show that myocardial structure abnormalities could be partially reversible in patients with GH secreting pituitary adenomas, but the best time for surgery and to preventing cardiac remodeling needs further study.
Conclusion
Cardiac manifestations in GH secreting pituitary adenomas involve needs the standardized approaches that include endoscopic surgery with medical therapy to maintaining the level of GH is required. Effective treatment is essential for pituitary adenomas that complicated by acromegaly cardiomyopathy, which may improve symptoms and results in a higher quality of life.
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